A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review

Selective rearranged during transfection (RET) tyrosine kinase inhibitor, pralsetinib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with RET gene mutations or fusions in clinical trials. While the latter focused on the risk of pneumonitis, there is a lack of data...

Celý popis

Podrobná bibliografie

Hlavní autoři:	François Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, Iphigénie Korakis, Giulia Leonardi, Marine Joly, Julien Mazières, Rosine Guimbaud, Nadim Fares, Emily Alouani
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-07-01
Edice:	Frontiers in Medicine
Témata:	pralsetinib RET inhibitor infection JAK/STAT case report
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1402902/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!